You are on page 1of 4
© Globatlen tb Novartis Q Search Home > About > Therapeuticareas > Neuroscience At Novartis, in Neuroscience, we are committed to understanding and solving some of the most burdensome neurological conditions to improve the quality of life for patients and their caregivers, and to make positive impact on society. We aim to lead the discovery, development and delivery of innovative medicines to create a transformational impact for people living with severe neurological conditions by changing the course of disease progression. Through innovation, partnerships and community engagement, we have been tackling neurological conditions for >80 years, launching transformative treatments which have made meaningful differences to millions of people worldwide. We continue to collaborate on the ‘Your privacy’ important for us. Wouse cookies taenhance your experionce when visting our websites performance cookies show show youuse the webste futons cooks remember yourprelerences sndtargetng cookies help ust share content relevanto you Select Cooke Setings for ‘managing the tferentcookes Youcan change your cookie stings atanyportotime by pressing he cooke setngstinkon theese ore disease areas tb Novartis @ Ghobailon » graine raine isa sorious and distinct rological disease affecting 1 billion ple worldwide, andimpacting women 0 times more than men. Migraine. Neuroscience stories ‘Your privacy is important for us. Wouse cookies taemhance your experience when Ving our Wetstes per cools show show youuse the webste functonal cooks remember you pete sndtargetng cookies helpustost ‘managing the cterentcookes Yous tert relevant‘o you Select Cocke Setings for change yeu cookie settings tay peitottime by pressing he cooke settngstinkon theese Inneuroscience, “an inflection point © Globatlen tb Novartis Fighting MS through innovation Investing in innovative treatments is vital to alleviate the suffering caused by multiple sclerosis (MS). atest neuroscience news 25,2028 Maa Release Sandoz receives FDA approval for Tyruko® atalizumab-sztn), first and only FDA-approved biosimilar ‘or relapsing forms of multip... ‘Your privacy is important for us. Wouse cookies taemhance your experience when Ving our Webstes per cookies show ushow youuse the webste functors cookies remember you pete sndtargetng cookies helpustost ‘managing the cterentcookes Yous pressing he cooke setngstinkon theese tert televat‘o you Select Cooke Setings for change you ceckie settings tay peitottimeby sn 20,2028 Mecilesse Novartis publishes new five- jear efficacy dataon

You might also like